Literature DB >> 10475388

Safe pulmonary resection after chemotherapy and high-dose thoracic radiation.

J R Sonett1, M J Krasna, M Suntharalingam, J Schuetz, L A Doyle, R Lilenbaum, Z Gamliel.   

Abstract

BACKGROUND: Pulmonary resection after high-dose thoracic irradiation is reported to be associated with a high morbidity and mortality, and has been considered to be prohibitive.
METHODS: We report safe pulmonary resection in 19 consecutive patients receiving neoadjuvant therapy that included greater than 59 Gy thoracic radiation. The mean thoracic radiation dose was 61.8 Gy (range 59.5-66.5) and mean age was 52 years (range 36-72 years). Cell type was adenocarcinoma (6), squamous (7), and other non-small cell lung cancer (NSCLC) (6). Sixteen of 19 patients received concurrent chemotherapy. Median time from end of treatment to surgical resection was 89 days (range 22-258 days). Surgical resection included 13 lobectomies and six pneumonectomies (four right, two left).
RESULTS: A complete pathologic response was seen in 8 of 19 (42%) patients. Three patients required intraoperative transfusion of blood. Mean intensive care unit stay was 2.0 days (range 1-8 days), and mean length of stay (LOS) was 8.0 days (range 3-18 days). There were four postoperative complications; one bronchopulmonary fistula, one subarachnoid-pleural fistula, and 2 patients with prolonged atelectasis. There was no incidence of acute respiratory distress syndrome (ARDS) or operative mortality.
CONCLUSIONS: Pulmonary resection, including pneumonectomy, after chemotherapy and high-dose thoracic radiation may be performed safely with a low rate of intraoperative and postoperative complications.

Entities:  

Mesh:

Year:  1999        PMID: 10475388     DOI: 10.1016/s0003-4975(99)00593-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839.

Authors:  Martin J Edelman; Chen Hu; Quynh-Thu Le; Jessica S Donington; Warren D D'Souza; Adam P Dicker; Billy W Loo; Elizabeth M Gore; Gregory M M Videtic; Nathaniel R Evans; Joseph W Leach; Maximilian Diehn; Steven J Feigenberg; Yuhchyau Chen; Rebecca Paulus; Jeffrey D Bradley
Journal:  J Thorac Oncol       Date:  2017-06-16       Impact factor: 15.609

2.  Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer.

Authors:  Min Kyu Kang; Yong Chan Ahn; Do Hoon Lim; Keunchil Park; Joon Oh Park; Young Mog Shim; Jhingook Kim; Kwhanmien Kim
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

Review 3.  Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision.

Authors:  In-Jae Oh; Sung-Ja Ahn
Journal:  Radiat Oncol J       Date:  2017-03-31

Review 4.  The management of the patient undergoing combined modality therapy for locally advanced non-small cell lung cancer.

Authors:  Martin J Edelman; Mohan Suntharalingam; Mark J Krasna
Journal:  Curr Treat Options Oncol       Date:  2003-02

5.  Case report of two patients having successful surgery for lung cancer after treatment for Grade 2 radiation pneumonitis.

Authors:  Yuki Nakajima; Hirohiko Akiyama; Hiroyasu Kinoshita; Maiko Atari; Mitsuro Fukuhara; Yoshihiro Saito; Hiroshi Sakai; Hidetaka Uramoto
Journal:  Ann Med Surg (Lond)       Date:  2015-11-26

6.  The long-term outcomes of induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.

Authors:  Hidetaka Uramoto; Hirohiko Akiyama; Yuki Nakajima; Hiroyasu Kinoshita; Takuya Inoue; Futoshi Kurimoto; Yu Nishimura; Yoshihiro Saito; Hiroshi Sakai; Kunihiko Kobayashi
Journal:  Case Rep Oncol       Date:  2014-10-23

7.  Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.

Authors:  Melissa A L Vyfhuis; Neha Bhooshan; Whitney M Burrows; Michelle Turner; Mohan Suntharalingam; James Donahue; Elizabeth M Nichols; Josephine Feliciano; Søren M Bentzen; Shahed Badiyan; Shamus R Carr; Joseph Friedberg; Charles B Simone; Martin J Edelman; Steven J Feigenberg; Pranshu Mohindra
Journal:  Adv Radiat Oncol       Date:  2017-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.